We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Growing Use of Robots in Labs

By Biotechdaily staff writers
Posted on 21 Apr 2005
The lack of highly skilled labor that has been a major issue for medical device manufacturers and clinical and pharmaceutical research laboratories has been solved by having robots substitute for human labor in these applications, according to a new analysis by Frost & Sullivan (Palo Alto, CA, USA), a global growth consulting company.

Robotic systems are increasingly being adopted in order to improve productivity and efficiency as the demand for more sophisticated medical devices and newer drugs continues to grow. More...
The new analysis revealed that the total market in North America for industrial robots for medical and pharmaceutical applications in 2004 was U.S.$384 million and is expected to reach $668 million by 2011.

Robots have great potential to enhance efficiency and throughput in clinical laboratories, where samples need to be delivered from patients' bedsides to the test equipment and then to the analyzers on a daily basis. This is due to the distinct advantage they have over human-based delivery methods in terms of quicker transportation and a much greater handling capacity.

"As technology improves, more features are likely to be added to robotics systems, not only for delivery but also for testing and analyzing the samples,” noted Kishan Bhat, a research analyst with Frost & Sullivan. "This will enhance the efficiency of the robots, and in turn, boost the throughput of the laboratories.”

However, industrial robotics manufacturers face several challenges in their efforts to establish themselves in medical and pharmaceutical applications. Key among these is the incompatibility of their controller software with existing installed equipment. In most cases, this proprietary software is not upgraded frequently to meet the changing application requirements. The introduction of open architecture controllers is expected to reduce this challenge, however.

The emergence of stand-alone workstations in pharmaceutical labs is another strong challenge. While these can handle liquids for microplates within a limited capacity, they do not need manual intervention during the process, are less expensive, and occupy less space than total automated robotics systems. Because of these advantages, many pharmaceutical labs are opting for partial automation of their facilities even though fully automated robotics systems are more flexible and accurate. An increasing number of labs are considering microfluidics as an effective way of reducing costs, because of their ability to miniaturize chemical assays and thereby increase portability.


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.